FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 9, 2026
Spruce Biosciences, Inc. (SPRB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $39.0 million. As of Jun 30, 2026 it held $96.3 million in cash and investments and $20.2 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-38.97M
+26.5% vs prior year
Operating cash flow (TTM)
$-42.62M
+17.2% vs year-ago TTM
Free cash flow
$-55.96M
-68.2% vs prior year
EPS
$-50.83
+47.3% vs prior year
Dividend per share
None
Shares outstanding
1.37M
-96.8% vs prior year
Net cash
$76.11M
as of Jun 30, 2026
Operating margin
-1143.4%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1683553
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | — | — |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M |
| Diluted EPS | -$50.83 | -$96.40 | -$1.24 | -$1.96 | — |
| Operating cash flow | -$33.3M | -$56.0M | -$33.3M | -$41.7M | -$35.9M |
| Free cash flow | — | -$56.0M | -$33.3M | -$41.7M | -$36.0M |
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M |
| Stockholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M |
| Cash and investments | $48.9M | $38.8M | $96.3M | $79.1M | $121.4M |
| Total debt | $736,000 | $2.9M | $5.0M | $7.0M | $6.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 366 Spruce Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.